MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Erasca Inc

Chiusa

1.16 -4.13

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.11

Massimo

1.17

Metriche Chiave

By Trading Economics

Entrata

-1M

-32M

EPS

-0.11

Dipendenti

103

EBITDA

1.5M

-35M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+313.22% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

19M

432M

Apertura precedente

5.29

Chiusura precedente

1.16

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 apr 2025, 22:38 UTC

Azioni calde

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 apr 2025, 21:53 UTC

Discorsi di Mercato

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 apr 2025, 21:44 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 apr 2025, 21:00 UTC

Notizie principali

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 apr 2025, 20:52 UTC

Discorsi di Mercato

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 apr 2025, 20:52 UTC

Notizie principali

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 apr 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 apr 2025, 20:48 UTC

Notizie principali

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 apr 2025, 20:45 UTC

Notizie principali

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 apr 2025, 20:32 UTC

Notizie principali

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 apr 2025, 20:21 UTC

Notizie principali

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 apr 2025, 20:00 UTC

Notizie principali

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 apr 2025, 19:51 UTC

Discorsi di Mercato

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 apr 2025, 19:37 UTC

Notizie principali

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 apr 2025, 19:32 UTC

Discorsi di Mercato

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 apr 2025, 19:28 UTC

Notizie principali

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 apr 2025, 19:15 UTC

Discorsi di Mercato

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 apr 2025, 19:12 UTC

Notizie principali

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 apr 2025, 19:11 UTC

Discorsi di Mercato

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 apr 2025, 19:09 UTC

Discorsi di Mercato

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 apr 2025, 19:09 UTC

Notizie principali

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 apr 2025, 19:00 UTC

Discorsi di Mercato

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 apr 2025, 18:53 UTC

Discorsi di Mercato

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 apr 2025, 18:51 UTC

Discorsi di Mercato

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 apr 2025, 18:44 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

4 apr 2025, 18:44 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

4 apr 2025, 18:44 UTC

Discorsi di Mercato

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 apr 2025, 18:43 UTC

Acquisizioni, Fusioni, Takeovers

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 apr 2025, 18:43 UTC

Acquisizioni, Fusioni, Takeovers

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 apr 2025, 18:39 UTC

Discorsi di Mercato

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

313.22% in crescita

Previsioni per 12 mesi

Media 5 USD  313.22%

Alto 6 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.04 / 1.49Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.